ArticleInternal medicine (Tokyo, Japan)2020
Usefulness and Limitations of a Serum Screening System to Predict the Risk of Gastric Cancer.
Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Infection-driven cancers in Asia: implications from epidemiological transitions.The Lancet regional health. Western Pacific · 2026Review
- The clinical value of analyzing predictive models for gastric function and gastric organic lesions.Frontiers in endocrinology · 2026Article
- Clinical Characteristics of Patients With Previous Helicobacter pylori Infection-Induced Atrophic Gastritis.Cureus · 2024Article
- [Type A, Type B, and Non-atrophic Gastritis].The Korean journal of helicobacter and upper gastrointestinal research · 2023Review
- Diagnostic performance of the normal range of gastrin calculated using strict criteria based on a combination of serum markers and pathological evaluation for detecting gastritis: a retrospective study.BMC gastroenterology · 2023Article
- Comparison of Gastric Cancer Risk Classifications Using Conventional and New Pepsinogen Criteria.Gastroenterology research and practice · 2023Article
- Gastric Cancer Screening in Japan: A Narrative Review.Journal of clinical medicine · 2022Review
- Application of a novel scoring system for gastric cancer opportunistic screening in hospital visits.BMC gastroenterology · 2022Article
- Serum Pepsinogens Combined with New Biomarkers Testing Using Chemiluminescent Enzyme Immunoassay for Non-Invasive Diagnosis of Atrophic Gastritis: A Prospective, Multicenter Study.Diagnostics (Basel, Switzerland) · 2022Article
- Clinical Value on Combined Detection of Serum CA724, DKK1, and TK1 in Diagnosis of Gastric Cancer.Journal of oncology · 2022Article
- Incidence of Infection among Subjects with Helicobacter pylori Seroconversion.Clinical endoscopy · 2022Article
- The Clinical Benefits, Limitations, and Perspectives of the ABC Method.Internal medicine (Tokyo, Japan) · 2020Article
- Population-Based Gastric Cancer Screening in Japan: Evolution, Challenges, and Lessons for Implementation.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective The aim of the present study was to evaluate the effectiveness and limitations of a serum screening system for predicting the risk of gastric cancer. Methods Serum pepsinogen I (PG I)/pepsinogen II (PG II) and Helicobacter pylori (HP) antibody levels were measured. Subjects were classified into four groupsaccording to their serological status (the ABC classification system). The grade of atrophic gastritis was assessed endoscopically. We evaluated gastric cancer detection rates according to the ABC classification system and the endoscopic grade of atrophy. Patients Individuals who underwent esophagogastroduodenoscopy (EGD) in a health check were prospectively enrolled in the present study. Results According to the ABC classification system, the gastric cancer detection rates in groups A, B, C, and D were 0.07% (4/6,105), 0.5% (8/1,739), 0.8% (16/2,010), and 1.1% (3/281), respectively. The gastric cancer detection rates in subjects with no atrophy, closed type (C-type) atrophy, and open type (O-type) atrophy were 0% (0/4,567), 0.2% (4/2,581), and 0.9% (27/2,987), respectively. In group A (HP(-)/PG(-)), the proportions of subjects with no atrophy, C-type atrophy, and O-type atrophy were 71.2%, 22.8%, and 6.0%, respectively. In group A, the gastric cancer detection rates in subjects with no atrophy, C-type atrophy, and O-type atrophy were 0%, 0.07%, and 0.8%, respectively. Conclusion The ABC classification system is useful for predicting the risk of gastric cancer. However, this system was limited in group A, which included individuals with a high risk of developing gastric cancer. An endoscopic diagnosis of atrophy may be more effective than the ABC classification system for predicting the risk of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.